# Metformin for Abdominal Aortic Aneurysm Growth Inhibition

> **NCT04224051** · PHASE2 · UNKNOWN · sponsor: **Uppsala University Hospital** · enrollment: 500 (estimated)

## Conditions studied

- Abdominal Aortic Aneurysm

## Interventions

- **DRUG:** Metformin
- **OTHER:** Standard care

## Key facts

- **NCT ID:** NCT04224051
- **Lead sponsor:** Uppsala University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-12
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2023-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04224051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04224051, "Metformin for Abdominal Aortic Aneurysm Growth Inhibition". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04224051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*